Correction to Appendix 4C and Quarterly Activities Report

Key points

• Net cash inflows from operating activities were A$2.77 million, correcting previous statement of net cash outflows
• Previous quarter cash balance corrected from $1,943,806 to $6,326,540
• Estimated Quarters of Funding Available corrected to 'N/A' due to positive net operating cash inflows

Full summary

Recce Pharmaceuticals Ltd has issued a correction to its previously released Appendix 4C and Quarterly Activities Report for the quarter ended 31 December 2024. The key corrections are: 1) The original report stated 'Net cash outflows from operating activities were (A$2.67 million)', which has been corrected to 'Net cash inflows from operating activities were A$2.77 million'. 2) The previous quarter's cash balance figure of $1,943,806 has been corrected to $6,326,540. 3) The 'Estimated Quarters of Funding Available' has been corrected to 'N/A' as the Company had positive net operating cash inflows and the remainder of that section is no longer applicable. There is no overall impact on the quarter end cash balance. A corrected Appendix 4C has been attached to the announcement.